Skip to main content

Bavaria Grants Kinaxo $900K for Chemical Proteomics

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies has received a grant of €575,000 ($906,000) from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport, and Technology.
 
Kinaxo plans to use the money to expand the uses for its chemical proteomics technology for identifying protein targets of compounds found in cell-based drug screens.
 
Martinsried, Germany-based Kinaxo’s Cellular Target Profiling technology was originally developed by the Max Planck Institute of Biochemistry, from which Kinaxo is a spin-off.
 
"This funding will allow us to significantly expand the scope and utility of our chemical proteomics capability, helping to demonstrate further valuable applications for broad adoption in the field of small molecule drug development," Kinaxo CEO Andreas Jenne said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.